Hemogenyx Pharmaceuticals PLC Announces Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) reported that Financial Controller Andrew Wright acquired 1,088,120 ordinary shares at an average price of 1.8288 pence per share, totaling £19,899.54. This purchase increases Wright's holding to 2,715,111 shares, approximately 0.50% of the company's issued capital. The transaction, disclosed under Market Abuse Regulation, occurred on May 18, 2021, on the London Stock Exchange. The company emphasizes compliance with regulations regarding insider information.
- Andrew Wright's share purchase may signal confidence in the company's future, potentially boosting investor sentiment.
- Wright now holds approximately 0.50% of the company, aligning interests with shareholders.
- None.
LONDON, UK / ACCESSWIRE / May 19, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of PDMR/person closely associated with them ("PCA") | |||||
a) | Name | Andrew Wright | ||||
b) | Position/status | PDMR: Financial Controller and Company Secretary | ||||
c) | Initial notification/ | Initial notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of Hemogenyx Pharmaceuticals plc | ||||
b) | Nature of the transaction | Standalone acquisition of shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
| ||||
e) | Date of the transaction | 2021-05-18 | ||||
f) | Place of the transaction | London Stock Exchange | ||||
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/648071/Hemogenyx-Pharmaceuticals-PLC-Announces-DirectorPDMR-Shareholding
FAQ
What share transaction was disclosed by Hemogenyx Pharmaceuticals on May 19, 2021?
How many total shares does Andrew Wright hold in Hemogenyx Pharmaceuticals?
What is the significance of the share purchase by Andrew Wright?
When did Andrew Wright conduct the share transaction?
What percentage of Hemogenyx Pharmaceuticals' issued share capital does Andrew Wright own?
